Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPYREAN: Empagliflozin vs sitagliptin and cardiac autonomic nerve activity in Japanese type 2 diabetes
jRCTs031180043Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm with Sitagliptin arm (2 arms). Primary endpoint: Change in LF/HF at 24 weeks. Started Jan 2018; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180043.